* Immunoprecise Antibodies Ltd IPA.OQ IPA.O is expected
to show a rise in quarterly revenue when it reports results on
March 14 for the period ending January 31 2024
* The Victoria British Columbia-based company is expected
to
report a 17.3% increase in revenue to C$6.068 million from
C$5.17 million a year ago, according to the mean estimate from 2
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Immunoprecise Antibodies
Ltd
is for a loss of 10 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for
Immunoprecise
Antibodies Ltd is $7.00, above its last closing price
of $1.75.
This summary was machine generated March 12 at 12:42 GMT. All
figures in Canadian dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)